Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 8.25% is 577% above its 5-year average of -1.73%, near the high end of its 5-year range (-7.13%–8.25%).
As of the fiscal period ended Tuesday, June 30, 2026. 68.79% above its 12-month average of 4.89%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 8.25%.
RETURN ON EQUITY (ROE)
8.25%
RETURN ON EQUITY (ROE) AVG TTM
4.89%
RETURN ON EQUITY (ROE) AVG 3Y
0.23%
RETURN ON EQUITY (ROE) AVG 5Y
-1.73%
RETURN ON EQUITY (ROE) AVG 10Y
-11.24%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+68.79%
CURRENT VS 3Y AVG
+3425.05%
CURRENT VS 5Y AVG
+577.37%
CURRENT VS 10Y AVG
+173.38%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+119.63%
vs the sector median at left
Veracyte, Inc.
Market Cap
$3.56B
Return on Equity (ROE)
8.25%
TTM Avg
4.89%
3Y Avg
0.23%
5Y Avg
-1.73%
Market Cap
$3.57B
Return on Equity (ROE)
-12.08%
TTM Avg
-47.33%
3Y Avg
-44.55%
5Y Avg
-54.96%
Market Cap
$3.54B
Return on Equity (ROE)
-32.94%
TTM Avg
-45.25%
3Y Avg
-31.88%
5Y Avg
-26.45%
Market Cap
$3.52B
Return on Equity (ROE)
-7.50%
TTM Avg
-76.90%
3Y Avg
-65.24%
5Y Avg
-51.68%
Market Cap
$3.64B
Return on Equity (ROE)
-73.75%
TTM Avg
-63.05%
3Y Avg
-54.60%
5Y Avg
-25.68%
Market Cap
$3.48B
Return on Equity (ROE)
-14.60%
TTM Avg
-18.51%
3Y Avg
-18.00%
5Y Avg
-17.65%
Market Cap
$3.47B
Return on Equity (ROE)
N/A
TTM Avg
-136.37%
3Y Avg
-87.14%
5Y Avg
-78.77%
Market Cap
$3.44B
Return on Equity (ROE)
-80.46%
TTM Avg
-68.44%
3Y Avg
592.63%
5Y Avg
329.15%
Market Cap
$3.38B
Return on Equity (ROE)
29.12%
TTM Avg
31.38%
3Y Avg
-1.34%
5Y Avg
-13.55%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Veracyte, Inc. (VCYT) | $3.56B | 8.25% | 4.89% | 0.23% | -1.73% |
| Tango Therapeutics, Inc. (TNGX)vs › | $3.57B | -12.08% | -47.33% | -44.55% | -54.96% |
| Xenon Pharmaceuticals Inc. (XENE)vs › | $3.54B | -32.94% | -45.25% | -31.88% | -26.45% |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.52B | -7.50% | -76.90% | -65.24% | -51.68% |
| Regencell Bioscience Holdings Limited (RGC)vs › | $3.64B | -73.75% | -63.05% | -54.60% | -25.68% |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.48B | -14.60% | -18.51% | -18.00% | -17.65% |
| Celcuity Inc. (CELC)vs › | $3.47B | N/A | -136.37% | -87.14% | -78.77% |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.44B | -80.46% | -68.44% | 592.63% | 329.15% |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.38B | 29.12% | 31.38% | -1.34% | -13.55% |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.36B | N/A | 336.99% | 336.99% | 336.99% |
ROE
8.2%
ROA
7.7%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 8.25% |
| 2026-03-31 | 6.55% |
| 2025-12-31 | 5.07% |
| 2025-09-30 | 2.41% |
| 2025-06-30 | 2.16% |
| 2025-03-31 | 2.77% |
| 2024-12-31 | 2.05% |
| 2024-09-30 | -0.79% |
| 2024-06-30 | -4.77% |
| 2024-03-31 | -6.09% |
| 2023-12-31 | -7.13% |
| 2023-09-30 | -4.74% |
| 2023-06-30 | -2.68% |
| 2023-03-31 | -2.79% |
| 2022-12-31 | -3.40% |
| 2022-09-30 | -4.13% |
| 2022-06-30 | -4.57% |
| 2022-03-31 | -4.44% |
| 2021-12-31 | -6.89% |
| 2021-09-30 | -6.60% |
| 2021-06-30 | -6.49% |
| 2021-03-31 | -6.68% |
| 2020-12-31 | -8.29% |
| 2020-09-30 | -8.12% |
| 2020-06-30 | -13.68% |
| 2020-03-31 | -9.72% |
| 2019-12-31 | -5.26% |
| 2019-09-30 | -3.57% |
| 2019-06-30 | -5.34% |
| 2019-03-31 | -18.79% |
| 2018-12-31 | -28.84% |
| 2018-09-30 | -35.68% |
| 2018-06-30 | -119.79% |
| 2018-03-31 | -106.51% |
| 2017-12-31 | -83.29% |
| 2017-09-30 | -62.98% |
| 2017-06-30 | -53.41% |
| 2017-03-31 | -55.30% |
| 2016-12-31 | -52.63% |
| 2016-09-30 | -116.54% |
| 2016-06-30 | -113.40% |
| 2016-03-31 | -83.52% |
| 2015-12-31 | -65.76% |
| 2015-09-30 | -58.52% |
| 2015-06-30 | -50.38% |
| 2015-03-31 | -86.40% |
| 2014-12-31 | -70.99% |
| 2014-09-30 | -56.18% |
| 2014-06-30 | -56.69% |
| 2014-03-31 | -50.43% |
| 2013-12-31 | -45.32% |
| 2013-06-30 | -275.32% |
